The Series B round was led by Kinnevik and Tencent to support product expansion and international growth.
"The world is seeing a tectonic shift in the way businesses work and hire: from local-first to global- and remote-first,"
Tencent uses technology to enrich the lives of internet users through communication services, advertising, fintech, and digital innovation.
The Series B round was led by Kinnevik and Tencent to support product expansion and international growth.
"The world is seeing a tectonic shift in the way businesses work and hire: from local-first to global- and remote-first,"
The financing round was co-led by Tencent and Flerie Invest to support Phase 1b clinical studies and pipeline expansion.
"This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome's therapeutic potential and Microbiotica's unique capabilities."
The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.
"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."
The financing round was backed by Tencent, British Patient Capital, CMB International, Mayfair Equity Partners, and IP Group.
"The metaverse concept is not new to Ultraleap. It has always been our mission to remove boundaries between physical and digital worlds. The pandemic has accelerated the rise of the term as more people now understand the power of enhancing the physical world with digital elements."
The funding round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group to support international expansion and technological development.
"This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals. This major injection of capital that now values us at $3billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion. As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem. I would also like to thank our existing investors for their long-term support."